Anzeige
Mehr »
Montag, 07.07.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AP32 | ISIN: US74366E1029 | Ticker-Symbol: PGF
Tradegate
04.07.25 | 11:12
43,400 Euro
+0,46 % +0,200
1-Jahres-Chart
PROTAGONIST THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
PROTAGONIST THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
43,20043,60009:32

Aktuelle News zur PROTAGONIST THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
Di H.C. Wainwright reiterates Buy rating on Protagonist Therapeutics stock17
30.06.Protagonist Therapeutics: Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity229A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), and glucagon (GCG) receptorsCompany...
► Artikel lesen
26.06.Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate190Webcast and conference call to be held on Monday, June 30th at 4:30 pm ET, dial in information below NEWARK, CA / ACCESS Newswire / June 26, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the...
► Artikel lesen
20.06.Citi Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs Opportunity3
17.06.Citi initiates Protagonist Therapeutics stock with buy rating on drug potential1
03.06.9 Analysts Assess Protagonist Therapeutics: What You Need To Know4
03.06.H.C. Wainwright bekräftigt Kaufempfehlung für Protagonist Therapeutics-Aktie2
PROTAGONIST THERAPEUTICS Aktie jetzt für 0€ handeln
03.06.H.C. Wainwright reaffirms Buy rating on Protagonist Therapeutics stock3
03.06.Clear Street lowers price target for Protagonist Therapeutics stock3
03.06.Clear Street senkt Kursziel für Protagonist Therapeutics-Aktie5
03.06.BTIG maintains buy rating on Protagonist Therapeutics stock1
23.05.Protagonist Therapeutics: EPS verfehlt Schätzungen um 0,13 $ - Umsatz schlechter als erwartet2
21.05.Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2025261NEWARK, CA / ACCESS Newswire / May 21, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will...
► Artikel lesen
09.05.Protagonist Therapeutics: Protagonist Announces Icotrokinra Phase 3 Data on Difficult-to-Treat Scalp and Genital Psoriasis and Preclinical Data on PN-881 Presented at the Society for Investigative Dermatology Annual Meeting328Data from icotrokinra ICONIC-TOTAL show 66% of patients with scalp psoriasis and 77% with genital psoriasis achieved site-specific clear or almost clear skin at Week 16Icotrokinra continues to demonstrate...
► Artikel lesen
06.05.Protagonist Therapeutics, Inc - 10-Q, Quarterly Report8
06.05.Protagonist Therapeutics, Inc - 8-K, Current Report3
06.05.Protagonist Therapeutics: Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update283Positive top line results from rusfertide Phase 3 VERIFY trial in polycythemia vera (PV) announced; full data selected for oral presentation during plenary session at ASCO on June 1stConference call...
► Artikel lesen
23.04.Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025275NEWARK, CA / ACCESS Newswire / April 23, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that an abstract was accepted for presentation at the Plenary Session at the...
► Artikel lesen
16.04.Protagonist Therapeutics Reports Granting of Inducement Award325NEWARK, CA / ACCESS Newswire / April 16, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company"), a clinical-stage biopharmaceutical company pioneering the discovery and development of...
► Artikel lesen
11.04.BTIG maintains Buy on Protagonist Therapeutics stock, $82 target3
Weiter >>
61 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1